摘要
Krüppel样转录因子2(Krüppel-like factor 2,KLF2)在内皮细胞炎症、血栓形成、血管生成以及巨噬细胞的炎症和极化等过程中发挥调节作用,上调KLF2的表达具有防治动脉粥样硬化的潜力。本研究利用KLF2表达上调剂筛选模型,从一株链霉菌CPCC 203909的大米发酵次级代谢产物中分离得到一个KLF2小分子上调剂曲古抑菌素C(trichostatin C,TSC)。TSC可以显著抑制肿瘤坏死因子α(tumor necrosis factorα,TNFα)诱导的单核细胞(THP-1)黏附到人脐静脉内皮细胞(human umbilical vein endothelial cells,HUVECs)上;Western blot实验结果表明,TSC具有抑制血管细胞黏附分子-1(vascular cell adhesion molecule-1,VCAM-1)的作用,从而减轻内皮细胞炎症;过表达组蛋白去乙酰化酶(histone deacetylase,HDAC)质粒转染和分子对接实验结果表明,TSC通过抑制HDAC 4/5/7来上调KLF2的表达。综上,TSC通过抑制HDAC 4/5/7上调KLF2的表达从而减轻TNFα诱导的内皮细胞炎症,具有预防和治疗动脉粥样硬化的潜力。
Krüppel-like transcription factor 2(KLF2)plays a key regulatory role in endothelial inflammation,thrombosis,angiogenesis and macrophage inflammation and polarization,and up-regulation of KLF2 expression has the potential to prevent and treatment atherosclerosis.In this study,trichostatin C(TSC)was obtained from the secondary metabolites of rice fermentation of Streptomyces sp.CPCC 203909 as a KLF2 up-regulator by using a high throughput screening model based on a KLF2 promoter luciferase reporter assay.TSC significantly inhibited the adhesion of tumor necrosis factor-α(TNFα)induced monocytes(THP-1)to human umbilical vein endothelial cells(HUVECs).Western blot results showed that TSC decreased TNFαinduced the protein expression increase of vascular cell adhesion molecule-1(VCAM-1),and thereby inhibited endothelial inflammation.The results of histone deacetylase(HDAC)overexpression and molecular docking experiments showed that TSC upregulated the expression of KLF2 by inhibiting subtypes of HDAC 4/5/7.In conclusion,this study suggests that TSC up-regulates the expression of KLF2 through inhibiting HDAC 4/5/7 and thus inhibits TNFαinduced endothelial inflammation,and it has the potential to prevent and treat atherosclerosis.
作者
雷丽娟
陈明华
李迎红
姜新海
王伟志
赵丽萍
王晨吟
陈渝川
张语嫣
巫晔翔
李顺旺
韩江雪
李依宁
盛任
张煜皓
张晶
余利岩
司书毅
许艳妮
LEI Li-juan;CHEN Ming-hua;LI Ying-hong;JIANG Xin-hai;WANG Wei-zhi;ZHAO Li-ping;WANG Chen-yin;CHEN Yu-chuan;ZHANG Yu-yan;WU Ye-xiang;LI Shun-wang;HAN Jiang-xue;LI Yi-ning;SHENG Ren;ZHANG Yu-hao;ZHANG Jing;YU Li-yan;SI Shu-yi;XU Yan-ni(NHC Key Laboratory of Biotechnology of Antibiotics,National Center for Screening Novel Microbial Drugs,Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)
出处
《药学学报》
CAS
CSCD
北大核心
2023年第8期2375-2383,共9页
Acta Pharmaceutica Sinica
基金
中国医学科学院医学与健康科技创新工程项目(2022-JKCS-10,2019-RC-HL-009,2021-1-I2M-030)
京津冀基础研究合作专项(19JCZD‐JC63900)
国家自然科学基金面上资助项目(81973328)。